ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer

0 views
September 27, 2024
0 Comments
Login to view comments. Click here to Login